Videos

At ATS 2026, Vallerie McLaughlin, MD discusses ADVANCE OUTCOMES showing ralinepag reduced PAH clinical worsening risk by 55% in pretreated patients.

This interview at ATS highlights key takeaways regarding new phase 3 data on AD109 for obstructive sleep apnea (OSA).

At ATS 2026, pooled phase 3 data showed mepolizumab reduced COPD exacerbations and hospitalizations in patients with blood eosinophil counts starting at 150 cells/µL.

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the presentations that they’re looking forward to at ADA 2026.

This interview at ATS 2026 highlights notable findings on the once-nightly oral pill, AD109, in obstructive sleep apnea (OSA).

At ATS 2026, phase 3b ENCORE findings showed amikacin liposome inhalation suspension achieved high culture conversion rates in newly diagnosed MAC lung disease.

Kyle Staller, MD, MPH, explains new real-world data showing 41% of IBS-C patients change treatments at least once, with each switch driving higher HCRU and provider portal burden.

Carel le Roux, PhD, MSC, discusses the investigative dual GLP-1/glucagon agonist’s weight loss efficacy in patients with obesity and overweight without T2D.

Freed discusses the evidence supporting treatment of iron deficiency before anemia develops, the symptom burden of non-anemic iron deficiency including fatigue, restless legs syndrome, and pica.

As dermatology patients enter clinical visits with information from social media, online forums, and AI inquiries, clinicians are juggling new concerns.

This episode covers key trial results and presentations to keep an eye on as ADA 2026 approaches.

In patients with COPD, heart rate measured during the 6-minute walk test were associated with greater hospital utilization, according to Andrew Truong-An Ho, MD, at ATS 2026.

At ATS 2026, Robert Wallis, MD, shared preliminary phase 2c data showing a novel 4-month pan-TB regimen containing sutezolid and N-acetylcysteine improved lung function recovery.

Maintenance extracorporeal photopheresis was associated with improved survival in lung transplant recipients with bronchiolitis obliterans syndrome, according to Alan Betensley, MD.

Fechner discusses the 2-year data from an open-label extension of the CAHtalyst Pediatric study, maintaining substantial glucocorticoid dose lowering.

Barry Borlaug, MD, discusses his recent publication collecting existing evidence on HFmrEF to reflect current data regarding treatment and management.

In this May episode of The Medical Sisterhood podcast, the show features guest Lisa Swanson, MD, discussing the emotional realities of pediatric dermatology.

Payam Dehghani, MD, discusses his sub-study of the NACMI registry, following patients with COVID-19 and STEMI who survived to hospital discharge.

Drs. Vin Gupta and Juanita Mora discuss the recent report and how it should inform clinician actions.

GI and liver safety signals for clinicians to know from the VISTAS evaluating volixibat in PSC-associated pruritus.

Schatz highlights the current limitations to a broader integration of T1D screening and suggests methods to circumvent these blockages.

Pugazhendhi Vijayaraman, MD, discusses his recent presentation of the final results of LEADR LBBAP, simplifying the lead placement problems faced by earlier models.

Kowdley explains phase 2b VISTAS data suggesting volixibat rapidly reduced PSC-associated pruritus in adults with limited treatment options.

Lucas Boersma, MD, PhD, discusses the 1-year results of the Enlighten study, highlighting effective defibrillation, low rate of complications, and high ATP success.

Lee discusess DDW 2026 data linking binge drinking frequency to advanced hepatic fibrosis in SLD.

Citrome discussed the limitations of indirect comparisons and the need for head-to-head trials evaluating adjunctive atypical antipsychotics for MDD, including lumateperone.

Susztak, MD, PhD, offers insight into a new score that predicts which APOL1 carriers will actually develop kidney disease.

This segment of a recent Skin of Color Savvy podcast highlights the experts' views on education related to colorism and skin pigment-related concerns.